Sasaki Hirofumi, Ishikawa Masakazu, Tanaka Nobuhiro, Nakanishi Kazuyoshi, Kamei Naosuke, Asahara Takayuki, Ochi Mitsuo
Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Spine (Phila Pa 1976). 2009 Feb 1;34(3):249-54. doi: 10.1097/BRS.0b013e3181913cde.
Magnetically isolated, peripheral blood-derived CD133+ cells were used as the therapeutic agent of spinal cord injury (SCI). A rat model was used to investigate the hypothesis that the cell therapy using this clinically accessible cell fraction could be an attractive option for injured spinal cord.
Given the capacity for the peripheral blood-derived CD133+ cells in vivo to produce neurogenesis via vasculogenesis as the feasible candidate for SCI in the clinical setting, the focus of the experiment was to investigate whether the cells could contribute to histologic and functional recovery of SCI after transplantation.
No evidence for peripheral blood-derived CD133+ cells application to SCI and no experimental studies showed functional recovery from SCI using this cell fraction have been published.
Contusion SCI was induced by placing a 25-g rod onto the spinal cord for 90 seconds in athymic nude rats. CD133+ cells or phosphate-buffered saline was administered intravenously immediately after SCI. The animals were analyzed at specific times after transplantation by several methods to examine histologic vasculogenesis and neurogenesis and to confirm functional recovery from SCI.
After cell transplantation, intrinsic angiogenesis and axonal regeneration were enhanced, and cavity formation was reduced in injured spinal cord, histologically, with significant functional recovery. Gene expression of vascular endothelial growth factor increased in the cell-administrated group.
The administration of CD133+ cells has a therapeutic potential to a rat spinal cord injury model and could be an optional treatment for spinal cord injury in the clinical settings.
磁珠分选的外周血来源的CD133+细胞被用作脊髓损伤（SCI）的治疗剂。采用大鼠模型来研究如下假设：使用这种临床可获取的细胞组分进行细胞治疗可能是脊髓损伤一种有吸引力的选择。
鉴于外周血来源的CD133+细胞在体内通过血管生成产生神经发生的能力，在临床环境中作为脊髓损伤的可行候选者，实验的重点是研究这些细胞在移植后是否有助于脊髓损伤的组织学和功能恢复。
尚无关于外周血来源的CD133+细胞应用于脊髓损伤的证据，也没有已发表的实验研究表明使用这种细胞组分可使脊髓损伤实现功能恢复。
在无胸腺裸鼠中，将一根25克的棒置于脊髓上90秒，诱导脊髓挫伤性损伤。脊髓损伤后立即静脉注射CD133+细胞或磷酸盐缓冲盐水。在移植后的特定时间，通过多种方法对动物进行分析，以检查组织学上的血管生成和神经发生，并确认脊髓损伤后的功能恢复情况。
细胞移植后，损伤脊髓的组织学检查显示，内源性血管生成和轴突再生增强，空洞形成减少，功能有显著恢复。细胞给药组中血管内皮生长因子的基因表达增加。
CD133+细胞给药对大鼠脊髓损伤模型具有治疗潜力，可能是临床环境中脊髓损伤的一种可选治疗方法。
